An interventional study of Experimental Denture Wipe and Tap Water in Denture Cleansers, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.
Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this two-phase study was to evaluate the oral and dermal tolerance of an experimental, non-rinse denture cleansing wipe after 7 and 14 days of use. In addition, the consumer acceptability of the denture cleansing wipes was also evaluated via a consumer acceptability questionnaire. A methodology was also evaluated to assess the efficacy of the denture wipe at removing food debris as exploratory objective.
This was a two phase single-center study. Phase 1 (Food removal testing), was monadic and only the wipe treatment was administered to complete upper dentures. Phase 1 participants then progressed to phase 2 (oral soft tissue [OST] and dermal assessment) which was an examiner blind parallel group, randomized and stratified (by denture type) design where both treatments (a single wipe and water control) were administered. Phase 2 participants included both fully and partially edentulous adult participants. Participants were not permitted to use any denture cleansers other than those provided and were not permitted to use denture fixatives for the duration of the study. The study comprised a Screening/Baseline visit and a 2 week Treatment Period with visits after 1 and 2 weeks use. Following screening participants who were eligible for Phase 1 were assessed for food migration adequacy. Participants consumed 30-32g (gram) of non-salted peanut halves in a controlled manner, then briefly rinsed their mouth with water and removed their upper denture. The investigator visually assessed the peanut particle migration underneath the denture on a 0-3 scale and those participants with a score greater than 0 were wiped by the participant with the experimental denture wipe. The mass of peanuts removed by the wipe and those remaining on the denture was subsequently measured. For a subset of participants (2 participants per peanut particle migration scale score), their dentures were photographed after peanut consumption both before and after use of the experimental denture wipe. Phase 1 participants then continued into Phase 2. All Phase 2 participants undertook an OST examination and a dermatological assessment of both sides of their lead hand, then randomized. The dental examiner and dermatologist were blinded to the treatment allocation. The results of these assessments served as the baseline reading. Participants were then instructed on the use of their assigned treatment with the first application undertaken and supervised at the study site. Participants were provided with a diary card to record their treatment applications and a consumer acceptability questionnaire to be completed at the time of their first at home treatment use. Participants were also provided with denture cleansing tablets for use overnight for the duration of the study in order to maintain denture hygiene. Participants returned to the study site after 7±3 and 14±3 days use of product for repeat OST and dermatological assessments.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
Device: Experimental Denture Wipe
Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
Other: Tap Water
Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.
Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use
Proportion of participants experiencing or reporting TE oral AEs on or before 14 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).
Time frame: up to 14 days
Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 7 Days of Use
Proportion of participants experiencing or reporting TE oral AEs on or before 7 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).
Time frame: up to 7 days
Proportion of Participants Experiencing Skin Irritation Scores of 2 or Greater After 7 and 14 Days of Use
Dermal assessment performed by a suitably qualified dermatologist on the front and back of the participant's dominant hand (hand with which participant used to hold the wipe during use) using skin irritation score that range from 0-4 as follows: 0 = no apparent cutaneous involvement, 0.5= equivocal reaction, 1= slight erythema with or without oedema, 2= moderate erythema, oedema with or without papules, 3= severe erythema, oedema with or without papules, 4= severe erythema, oedema with vesicles or blisters. Any site where skin irritation was scored ≥2, was visually assessed and reported.
Time frame: Day 7, Day 14
Number of Participants Responses for Consumer Acceptability Questionnaire Score
All the participants supplied with a consumer acceptability questionnaire (Question \[Q\] 1 to 4) to complete immediately before \& after their first use of treatment at home after eating a meal. The number of participants with individual score was reported. After eating \& before cleaning denture: Q1= how fresh does denture feel?, Q2= how clean does denture feel?; Look in the mirror and smile, now answer the following questions: Q3= after eating \& before cleaning, how clean does denture/smile look ?, Q4= after removing \& cleaning denture, how fresh does denture feel?, Q5= after removing \& cleaning denture, run your tongue over denture teeth, how clean does denture feel?, Q6= after removing \& cleaning denture, how clean does denture/smile look?, Q7= after removing \& cleaning denture, how satisfied are you with amount of debris removed? All questions were scored as follows for respective parameter(fresh/clean/satisfied): 0=Not at all, 1=slightly, 2=moderately, 3=very, 4=extremely.
Time frame: Day 7
All participants were recruited at one center in the United States.
| Milestone | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| Started | 31 | 0 |
| Completed | 31 | 0 |
| Not completed | 0 | 0 |
| Milestone | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| Started | 76 | 76 |
| Completed | 73 | 75 |
| Not completed | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
Proportion of participants experiencing or reporting TE oral AEs on or before 14 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).
| Proportion of participants | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use | 0.039 (0.01 to 0.11) | 0.013 (0.00 to 0.07) |
Proportion of participants experiencing or reporting TE oral AEs on or before 7 days of use treatments were reported. TE AEs include AEs that were identified during an oral soft tissue examination, a dermal assessment or reported by the subject. AEs were categorized as oral or non-oral by the Clinical Research scientist prior to database lock (oral AE's were AEs effecting tissues associated with the oral cavity extending from the labial mucosa to the pharyngeal area).
| Proportion of participants | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 7 Days of Use | 0.013 (0.00 to 0.07) | 0.000 (0.00 to 0.05) |
Dermal assessment performed by a suitably qualified dermatologist on the front and back of the participant's dominant hand (hand with which participant used to hold the wipe during use) using skin irritation score that range from 0-4 as follows: 0 = no apparent cutaneous involvement, 0.5= equivocal reaction, 1= slight erythema with or without oedema, 2= moderate erythema, oedema with or without papules, 3= severe erythema, oedema with or without papules, 4= severe erythema, oedema with vesicles or blisters. Any site where skin irritation was scored ≥2, was visually assessed and reported.
| Proportion of participants | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| At Day 7 | 0 | 0 |
| At Day 14 | 0 | 0 |
All the participants supplied with a consumer acceptability questionnaire (Question \[Q\] 1 to 4) to complete immediately before \& after their first use of treatment at home after eating a meal. The number of participants with individual score was reported. After eating \& before cleaning denture: Q1= how fresh does denture feel?, Q2= how clean does denture feel?; Look in the mirror and smile, now answer the following questions: Q3= after eating \& before cleaning, how clean does denture/smile look ?, Q4= after removing \& cleaning denture, how fresh does denture feel?, Q5= after removing \& cleaning denture, run your tongue over denture teeth, how clean does denture feel?, Q6= after removing \& cleaning denture, how clean does denture/smile look?, Q7= after removing \& cleaning denture, how satisfied are you with amount of debris removed? All questions were scored as follows for respective parameter(fresh/clean/satisfied): 0=Not at all, 1=slightly, 2=moderately, 3=very, 4=extremely.
| Participants | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| Q1: Score 0 - Not fresh at all | 20 | 18 |
| Q1: Score 1 - Slightly fresh | 16 | 26 |
| Q1: Score 2 - Moderately fresh | 18 | 17 |
| Q1: Score 3 - Very fresh | 14 | 10 |
| Q1: Score 4 - Extremely fresh | 8 | 5 |
| Q2: Score 0 - Not clean at all | 12 | 12 |
| Q2: Score 1 - Slightly clean | 12 | 23 |
| Q2: Score 2 - Moderately clean | 26 | 21 |
| Q2: Score 3 - Very clean | 15 | 14 |
| Q2: Score 4 - Extremely clean | 11 | 6 |
| Q3: Score 0 - Not clean at all | 5 | 1 |
| Q3: Score 1 - Slightly clean | 15 | 15 |
| Q3: Score 2 - Moderately clean | 23 | 31 |
| Q3: Score 3 - Very clean | 23 | 21 |
| Q3: Score 4 - Extremely clean | 10 | 8 |
| Q4: Score 0 - Not fresh at all | 0 | 0 |
| Q4: Score 1 - Slightly fresh | 0 | 3 |
| Q4: Score 2 - Moderately fresh | 11 | 22 |
| Q4: Score 3 - Very fresh | 32 | 31 |
| Q4: Score 4 - Extremely fresh | 33 | 20 |
| Q5: Score 0 - Not clean at all | 0 | 1 |
| Q5: Score 1 - Slightly clean | 1 | 0 |
| Q5: Score 2 - Moderately clean | 9 | 18 |
| Q5: Score 3 - Very clean | 32 | 37 |
| Q5: Score 4 - Extremely clean | 34 | 20 |
| Q6: Score 0 - Not clean at all | 0 | 0 |
| Q6: Score 1 - Slightly clean | 1 | 1 |
| Q6: Score 2 - Moderately clean | 10 | 18 |
| Q6: Score 3 - Very clean | 33 | 37 |
| Q6: Score 4 - Extremely clean | 32 | 20 |
| Q7: Score 0 - Not satisfied at all | 0 | 0 |
| Q7: Score 1 - Slightly satisfied | 0 | 0 |
| Q7: Score 2 - Moderately satisfied | 9 | 21 |
| Q7: Score 3 - Very satisfied | 40 | 36 |
| Q7: Score 4 - Extremely satisfied | 27 | 19 |
Collected over Approximately 17 days (from Screening Visit to Visit 3). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Denture Wipe | 0/76 (0%) | 0/76 (0%) | 3/76 (3.9%) |
| Water Rinse | 0/76 (0%) | 0/76 (0%) | 1/76 (1.3%) |
| Event | Experimental Denture Wipe | Water Rinse |
|---|---|---|
| Mouth InjuryInjury, poisoning and procedural complications | 2/76 | 0/76 |
| Lip InjuryInjury, poisoning and procedural complications | 1/76 | 0/76 |
| Tongue coatedGastrointestinal disorders | 0/76 | 1/76 |
Baseline assessment was performed on safety population, which included all participants who were randomized and received treatment at least once during the study.
| Age, Continuous(years) | Experimental Denture Wipe | Water Rinse | Total |
|---|---|---|---|
| Mean | 60.99 ± 12.702 | 61.03 ± 12.622 | 61.01 ± 12.620 |
| Sex: Female, Male(Participants) | Experimental Denture Wipe | Water Rinse | Total |
|---|---|---|---|
| Female | 57 | 48 | 105 |
| Male | 19 | 28 | 47 |
| Race (NIH/OMB)(Participants) | Experimental Denture Wipe | Water Rinse | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 10 | 8 | 18 |
| White | 64 | 67 | 131 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
Ran from Oct 2016 to primary completion in Oct 2016, 0 months.
Results were first posted in Aug 2018, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.